Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review

BMC Pulmonary Medicine

Table 1 Study characteristics.

First author, year	Centers	Population	Primary endpoint	Comparator regimen	Minimum doses
Chastre, 2008 [39]	M	VAP	C/M success	Doripenem	1
Yanagihara, 2005 [40]	S	CAP	C/M success	Sulbactam/ampicillin	6
Schmit, 2006 [41]	M	NP	Clinical response	Piperacillin/tazobactam	1
Joshi, 2006 [42]	M	NP	Clinical response	Piperacillin/tazobactam	1
Romanelli, 2006 [43]	M	CAP	C/M success	Meropenem	NR
Shorr, 2005 [44]	M	VAP	Clinical success	Levofloxacin/ceftazidime	NR
Zanetti, 2003 [45]	M	NP	C/M success	Cefepime	NR
West, 2003 [46]	M	NP	C/M success	Levofloxacin/ceftazidime	1
Torres, 2000 [47]	M	VAP	C/M success	Ciprofloxacin	1
Bartoloni, 1999 [48]	M	CAP	Clinical response	Meropenem
Jaccard, 1998 [49]	M	Mixed	Clinical success	Piperacillin/tazobactam	5
Marra*, 1998 [50]	S	Mixed	C/M success, resistance	Piperacillin/tazobactam	1
Ho, 1997 [51]	NR	CAP	Clinical success	Ceftazidime	NR
Raad, 1996 [52]	S	Mixed	C/M success	Aztreonam/vancomycin	NR
Vic, 1996 [53]	S	Mixed	Bacteriological parameters	Ceftazidime/amikacin	NR
Bohme, 1995 [54]	NR	Mixed	C/M success	Ceftazidime/piperacillin	NR
Siami, 1995 [55]	M	CAP & NP	Safety	Ciprofloxacin	15
Cometta, 1994 [56]	M	Mixed	Tolerance	Imipenem/netilmycin	NR
Fink, 1994 [57]	M	CAP & NP	C/M success	Ciprofloxacin	1
Norrby, 1993 [58]	M	Mixed	C/M success	Ceftazidime	NR

M: multicenter, S: single center, NR: not reported, C/M: clinical/microbiological, VAP: ventilator-associated pneumonia, CAP: community-acquired pneumonia, ICU: intensive care unit, NP: nosocomial pneumonia, NR: not reported, CF: cystic fibrosis, PA: Pseudomonas aeruginosa
*Although this study did not explicitly report on PA outcomes, it was included because it was one of the few studies specifically reporting zero incidence of C. difficile diarrhea

ISSN: 1471-2466